Trial Profile
Pharmacokinetics of sacituzumab govitecan (IMMU-132) in patients with diverse advanced solid tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Apr 2017
Price :
$35
*
At a glance
- Drugs Sacituzumab govitecan (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- 12 Apr 2017 New trial record
- 05 Apr 2017 Results presented at the 108th Annual Meeting of the American Association for Cancer Research